Analytical performance of the FDA-cleared Parsortix® PC1 system
Journal of Circulating Biomarkers · 07.08.2023 · 12 · 26-33
DOI: 10.33393/jcb.2023.2629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Circulating Biomarkers, online erschienen am 07.08.2023. Verfasst von Amy Templeman und 15 weiteren Autor:innen. Beteiligte Einrichtung: ANGLE Europe Limited, Guildford - UK. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The Parsortix® PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of circulating tumor cells from whole blood based on cell size and deformability. This report details the analytical characterization of linearity, detection limit, precision, and reproducibility for this device.
Methods
System performance was determined using K2-EDTA blood samples collected from self-declared healthy female volunteers (HVs) and MBC patients spiked with prelabeled cultured breast cancer cell lines (SKBR3, MCF7, or Hs578T). Samples were processed on Parsortix® PC1 systems and captured cells were harvested and enumerated.
Results
The system captured and harvested live SKBR3, MCF7, and Hs578T cells and fixed SKBR3 cells linearly between 2 and ~100 cells, with average harvest rates of 69%, 73%, 79%, and 90%, respectively. To harvest ≥1 cell ≥95% of the time, the system required 3, 5 or 4 live SKBR3, MCF7 or Hs578T cells, respectively. Average harvest rates from precision studies using 5, 10, and ~50 live cells spiked into blood for each cell line ranged from 63.5% to 76.2%, with repeatability and reproducibility percent coefficient of variation (%CV) estimates ranging from 12.3% to 32.4% and 13.3% to 34.1%, respectively. Average harvest rates using ~20 fixed SKBR3 cells spiked into HV and MBC patient blood samples were 75.0% ± 16.1% (%CV = 22.3%) and 68.4% ± 14.3% (%CV = 21.1%), respectively.
Conclusions
These evaluations demonstrate the Parsortix® PC1 system linearly and reproducibly harvests tumor cells from blood over a range of 1 to ~100 cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ANGLE Europe Limited, Guildford - UK.
- ANGLE North America, Inc., Plymouth Meeting, PA - USA.
- TMDx Consulting LLC, Schwenksville, PA - USA.
- Whitings LLP, Ramsey - UK.
- Petmedix, Cambridge - UK.
- Royal Berkshire NHS Foundation Trust, Bracknell - UK.
Zitieren
APA
Templeman, A., Miller, M. C., Cooke, M. J., O'Shannessy, D. J., Gurung, Y., Pereira, T., Peters, S. G., Piano, M., Teo, M., Khazan, N., Kim, K., Cohen, E., Lopez, H. B., Alvarez, F., Ciccioli, M., & Pailhes-Jimenez, A. S. (2023). Analytical performance of the FDA-cleared Parsortix® PC1 system. Journal of Circulating Biomarkers, 12, 26-33. https://doi.org/10.33393/jcb.2023.2629
Vancouver
Templeman A, Miller MC, Cooke MJ, O'Shannessy DJ, Gurung Y, Pereira T, et al. Analytical performance of the FDA-cleared Parsortix® PC1 system. Journal of Circulating Biomarkers. 2023;12:26-33. doi:10.33393/jcb.2023.2629
BibTeX
@article{Templeman2023,
author = {Templeman, Amy and Miller, M Craig and Cooke, Martin J and O'Shannessy, Daniel J and Gurung, Yuwaraj and Pereira, Tiago and Peters, Samuel G and Piano, Mario De and Teo, Manilyn and Khazan, Negar and Kim, Kyukwang and Cohen, Evan and Lopez, Heather B and Alvarez, Franklin and Ciccioli, Mariacristina and Pailhes-Jimenez, Anne-Sophie},
title = {Analytical performance of the FDA-cleared Parsortix® PC1 system},
journal = {Journal of Circulating Biomarkers},
year = {2023},
volume = {12},
pages = {26--33},
doi = {10.33393/jcb.2023.2629}
}
EUVIMED